Core Viewpoint - The approval of Cefiderocol in China marks a significant entry point for Shionogi Pharmaceutical into the Chinese market, which is primarily dominated by generic drugs [2][4]. Group 1 - Cefiderocol, a drug for treating antibiotic-resistant infections, has been approved for production and sales in China as of January 8 [2]. - The drug is already being sold in 26 countries and regions, including Japan and Europe, with steady sales growth [2]. - Shionogi aims to leverage the sales experience gained from Cefiderocol in Western markets to accelerate its early deployment in China [4]. Group 2 - The approval was based on results from international joint clinical trials conducted overseas and domestic clinical trials in China, confirming the drug's efficacy and safety [4]. - Shionogi plans to launch multiple products in China by the fiscal year 2030, including a COVID-19 treatment drug named "Xocova" [4].